Avadel Pharmaceuticals plc (AVDL)
21.64
+0.01 (0.05%)
Inactive · Last trade price on Feb 11, 2026

Avadel Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
248.52169.1227.96--22.33
Revenue Growth (YoY)
79.88%504.79%----62.28%
Cost of Revenue
12.6415.280.85--5.74
Gross Profit
235.88153.8427.12--16.59
Selling, General & Admin
191.46181.04151.7174.5268.532.41
Depreciation & Amortization Expenses
-----0.41
Research & Development
39.8915.213.2620.717.120.44
Other Operating Expenses
---3.35-0.0549.04
Total Operating Expenses
231.36196.24164.9798.5685.55102.3
Operating Income
4.52-42.4-137.85-98.56-85.555.82
Interest Income
1.934.150.09-0.542.34-0.83
Interest Expense
-9.71-10.83-9.89-12.34-9.94-12.99
Other Non-Operating Income (Expense)
---13.13--2.93
Total Non-Operating Income (Expense)
-7.78-6.68-22.93-12.88-7.6-10.9
Pretax Income
-3.26-49.08-160.78-111.44-93.15-5.08
Provision for Income Taxes
--0.25-0.526.03-15.82-12.11
Net Income
-0.28-48.83-160.28-137.46-77.337.03
Net Income to Common
-0.28-48.83-160.28-137.46-77.337.03
Shares Outstanding (Basic)
979580605953
Shares Outstanding (Diluted)
989580605955
Shares Change (YoY)
5.19%18.67%33.41%2.66%6.54%46.89%
EPS (Basic)
-0.00-0.51-2.00-2.29-1.320.13
EPS (Diluted)
-0.00-0.51-2.00-2.29-1.320.13
Free Cash Flow
34.54-46.91-128.51-71.02-77.34-48.83
Free Cash Flow Per Share
0.35-0.49-1.60-1.18-1.32-0.89
Gross Margin
94.91%90.97%96.97%--74.29%
Operating Margin
1.82%-25.07%-492.97%--26.04%
Profit Margin
-0.11%-28.87%-573.17%--31.47%
FCF Margin
13.90%-27.74%-459.58%---218.64%
EBITDA
8.2-39.72-136.08-97.07-84.737.51
EBITDA Margin
3.30%-23.49%-486.65%--33.60%
EBIT
4.52-42.4-137.85-98.56-85.555.82
EBIT Margin
1.82%-25.07%-492.97%--26.04%
Effective Tax Rate
-0.50%0.31%-23.35%16.98%238.29%
Updated Nov 4, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q